39 research outputs found
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy.
OBJECTIVE: To externally validate the prognostic value of lymphovascular invasion
(LVI) in a large international cohort of patients treated with radical cystectomy
(RC) for urothelial carcinoma of the bladder (UCB).
PATIENTS AND METHODS: We collected data from 4257 patients treated with RC and
pelvic lymphadenectomy for UCB, without neoadjuvant chemotherapy, at 12 centres.
LVI was defined as presence of nests of tumour cells within an endothelium-lined
space.
RESULTS: LVI was detected in 1407 patients (33.1%); the proportion of LVI
increased with advancing stage, higher grade, soft-tissue surgical margin
involvement, and lymph node metastasis (P < 0.001 for all). In standard
multivariate models, LVI was associated with both disease recurrence (hazard
ratio 1.43, P < 0.001) and cancer-specific mortality (1.45, P < 0.001). In the
entire cohort, adding LVI to a base model that included standard features
improved only minimally its predictive accuracy for both recurrence and
cancer-specific mortality (by 1.1% and 1.2%, respectively). In 3122 patients with
negative lymph nodes, LVI remained independently associated with and improved the
predictive accuracy of the standard predictors for recurrence (hazard ratio 1.68,
P < 0.001; +2.3%) and cancer-specific mortality (1.70, P < 0.001; +2.4%). By
contrast, in 1071 node-positive patients, LVI only marginally improved the
prediction of cancer-specific recurrence (hazard ratio 1.20, P < 0.001; +0.2%)
and survival (1.23, P < 0.001; +0.5%).
CONCLUSIONS: LVI is strongly associated with clinical outcome in node-negative
patients treated with RC. The assessment of LVI might help to identify patients
who could benefit from adjuvant therapy after RC. After confirmation in different
populations, LVI should be included in the staging of UCB
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
PURPOSE:
We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort.
METHODS:
Univariate and multivariate logistic regression models targeted histologically confirmed disease recurrence, and focused on 2,542 patients with bladder TCC from 10 participating centers. Variables consisted of pre-cystoscopy voided urine Nuclear Matrix Protein 22 (NMP22) assay, urine cytology, age and gender. Resulting nomograms were internally validated with bootstrapping. Nomogram performance was explored graphically with Loess smoothing plots.
RESULTS:
Overall 957 patients had recurrent TCC. Tumor grade and stage was available for 898 patients, including 24% grade I, 43% grade II, and 33% grade III; 45% stage Ta, 32% T1 and/or CIS, and 23% T2 or greater. Bootstrap corrected predictive accuracy for any TCC recurrence was 0.842; grade III Ta/T1 or CIS was 0.869; and T2 or higher stage TCC of any grade was 0.858. Virtually perfect performance characteristics were observed for the nomograms predicting any TCC recurrence or grade III Ta/T1 or CIS. The nomogram predicting T2 or higher stage TCC overestimated the observed probability for predicted values greater than 45%.
CONCLUSIONS:
We developed and internally validated nomograms that incorporate urinary NMP22, cytology, age and gender to predict with high accuracy the probability of disease recurrence and progression in patients with Ta, T1, and/or CIS bladder TCC. These nomograms could provide a means for individualizing followup in patients with Ta, T1, CIS bladder TC